Brentuximab Vedotin

The Formulary Management Expert Committee (FMEC) recommends that brentuximab vedotin as part of BrECADD (brentuximab vedotin, etoposide, cyclophosphamide, doxorubicin, dacarbazine, and dexamethasone) be reimbursed for the treatment of adult patients with newly diagnosed, advanced-stage, classical Hodgkin lymphoma (cHL) provided certain conditions are met. Brentuximab vedotin as part of BrECADD may be initiated for the treatment of cHL if all the following conditions are met: adult patient with newly diagnosed cHL, advanced-stage (stage III or IV or stage II with B symptoms and 1 or both risk factors of large mediastinal mass or extranodal involvement), and good performance status. Brentuximab vedotin should be discontinued if there are either of the following: disease progression or unacceptable toxicities. Initiation of brentuximab vedotin as part of BrECADD should be limited to clinicians with expertise in the diagnosis and management of Hodgkin lymphoma (HL). A price reduction may be required.